Novartis

ADAKVEO

View Prices
  1. Home
    2.  / 
  2. J Code
    3.  / ADAKVEO – J0791

Manufacturer:

Novartis

Name:

ADAKVEO

HCPCS Code Descriptor:

Injection, crizanlizumab-tmca, 5 mg

Category:

J Code

HCPCS:

J0791

NDC(s):

00078-0883-61

Primary Type:

Oncology-Anti-Emetic

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

ADAKVEO is an Oncology-Anti-Emetic drug manufactured by Novartis and administered via the Intravenous route of administration. The J Code: J0791 is aligned to the drug ADAKVEO.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/20

HCPCS Effective Date:

7/1/20

HCPCS Short Description:

Inj crizanlizumab-tmca 5mg

Billing and Coding Guide:

https://www.hcp.novartis.com/globalassets/migration-root/hcp/products2/adakveo/resources/billing-coding-guide.pdf

Patient Assistance:

https://www.patient.novartisoncology.com/financial-assistance/pano/

https://copay.novartisoncology.com/